Related Experiment Video
Updated: Jul 13, 2026
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Continuous dopaminergic stimulation--from theory to clinical practice
1Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy. angelo3000@yahoo.com
For advanced Parkinson's disease (PD), duodenal levodopa offers significant motor improvement without behavioral side effects. This therapy allowed patients to discontinue other PD medications, suggesting it as a valuable option.
Area of Science:
- Neurology
- Neurosurgery
- Pharmacology
Background:
- Advanced Parkinson's disease (PD) presents challenges with motor fluctuations and dyskinesia.
- Current management includes subthalamic nucleus deep brain stimulation (STN-DBS), subcutaneous apomorphine, and duodenal levodopa infusion.
Purpose of the Study:
- To compare the efficacy and safety of STN-DBS, apomorphine infusion, and duodenal levodopa in advanced PD patients.
- To report clinical experience with these advanced therapies at a single center.
Main Methods:
- Retrospective review of patients with advanced PD treated with STN-DBS, apomorphine infusion, or duodenal levodopa.
- Assessment of motor fluctuations, dyskinesia, and adverse events, including behavioral changes.
Main Results:
- Apomorphine infusion reduced 'off' time but did not improve dyskinesia and was linked to impulse control disorders.
- STN-DBS improved motor symptoms but was associated with adverse behavioral changes.
- Duodenal levodopa provided significant clinical benefit, improved motor function, and eliminated the need for other PD medications without causing behavioral issues.
Conclusions:
- Duodenal levodopa is a highly effective treatment for advanced Parkinson's disease, offering substantial clinical benefits.
- Duodenal levodopa should be strongly considered for patients with advanced PD experiencing motor fluctuations and dyskinesia.
- This therapy may simplify medication regimens and improve quality of life in advanced Parkinson's disease patients.
More Related Videos
11:26Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
Published on: September 21, 2017
07:41Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
Published on: June 5, 2017
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
01:21Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...